X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15060) 15060
Book Review (3257) 3257
Publication (597) 597
Magazine Article (65) 65
Conference Proceeding (41) 41
Book Chapter (24) 24
Book / eBook (17) 17
Dissertation (2) 2
Paper (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13752) 13752
humans (10968) 10968
hypolipidemic agents - therapeutic use (8518) 8518
male (7620) 7620
animals (5040) 5040
female (4935) 4935
hypolipidemic agents - pharmacology (4372) 4372
middle aged (3980) 3980
rats (2846) 2846
aged (2784) 2784
adult (2670) 2670
risk factors (2549) 2549
hyperlipidemias - drug therapy (2458) 2458
cholesterol (2286) 2286
pharmacology & pharmacy (2233) 2233
triglycerides - blood (2173) 2173
lipids - blood (1928) 1928
hypolipidemic agents - administration & dosage (1906) 1906
cholesterol - blood (1902) 1902
abridged index medicus (1723) 1723
cardiac & cardiovascular systems (1542) 1542
cholesterol, ldl - blood (1480) 1480
treatment outcome (1479) 1479
hypolipidemic agents - adverse effects (1462) 1462
lipids (1394) 1394
mice (1384) 1384
atherosclerosis (1339) 1339
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1291) 1291
medicine, general & internal (1279) 1279
cholesterol, hdl - blood (1220) 1220
cardiovascular diseases - prevention & control (1148) 1148
coronary-heart-disease (1061) 1061
dyslipidemias - drug therapy (1043) 1043
statins (1030) 1030
liver - metabolism (988) 988
drug therapy, combination (986) 986
liver - drug effects (986) 986
cardiovascular disease (939) 939
hyperlipidemias - blood (930) 930
risk (915) 915
peripheral vascular disease (901) 901
hypercholesterolemia - drug therapy (886) 886
prevention (859) 859
diabetes (858) 858
endocrinology & metabolism (849) 849
time factors (834) 834
clinical trials as topic (800) 800
biochemistry & molecular biology (786) 786
antihypertensive agents - therapeutic use (783) 783
triglycerides (772) 772
rats, wistar (771) 771
hyperlipidemia (736) 736
fenofibrate - therapeutic use (732) 732
coronary disease - prevention & control (724) 724
hypoglycemic agents - therapeutic use (723) 723
metabolism (722) 722
cardiovascular-disease (716) 716
hypercholesterolemia (714) 714
drug therapy (709) 709
chemistry, medicinal (702) 702
dose-response relationship, drug (700) 700
hypolipidemic agents - chemistry (687) 687
simvastatin (681) 681
myocardial-infarction (678) 678
diet (674) 674
fenofibrate (674) 674
disease (672) 672
rats, sprague-dawley (662) 662
hyperlipidemias - complications (660) 660
research (648) 648
hypolipidemic agents (644) 644
dyslipidemia (628) 628
diabetes mellitus, type 2 - drug therapy (623) 623
care and treatment (618) 618
therapy (615) 615
double-blind method (602) 602
analysis (595) 595
mortality (585) 585
health aspects (583) 583
biomarkers - blood (580) 580
cardiovascular diseases - etiology (572) 572
lipid metabolism (570) 570
lipoproteins (562) 562
lipoproteins - blood (557) 557
diabetes mellitus, type 2 - complications (549) 549
fenofibrate - pharmacology (549) 549
niacin - therapeutic use (549) 549
liver (534) 534
low density lipoproteins (534) 534
insulin resistance (527) 527
plant extracts - pharmacology (527) 527
practice guidelines as topic (521) 521
hypoglycemic agents - pharmacology (516) 516
aged, 80 and over (514) 514
blood glucose - metabolism (510) 510
risk assessment (507) 507
secondary prevention (502) 502
anticholesteremic agents (499) 499
follow-up studies (492) 492
cardiovascular diseases (488) 488
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12935) 12935
German (402) 402
French (334) 334
Russian (292) 292
Spanish (255) 255
Chinese (218) 218
Japanese (157) 157
Italian (147) 147
Polish (96) 96
Czech (70) 70
Hungarian (53) 53
Swedish (32) 32
Portuguese (30) 30
Danish (25) 25
Norwegian (23) 23
Dutch (20) 20
Finnish (15) 15
Romanian (11) 11
Ukrainian (10) 10
Lithuanian (7) 7
Slovak (7) 7
Bulgarian (5) 5
Croatian (4) 4
Korean (4) 4
Serbian (3) 3
Turkish (3) 3
Hebrew (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1975, ISBN 9780387073613, Volume 41. Bd., xiii, 488
Book
Food and Function, ISSN 2042-6496, 12/2014, Volume 6, Issue 1, pp. 296 - 33
Beneficial effects of green tea ( Camellia sinensis , Theaceae) extracts against obesity have been reported; however, the anti-obesity ability of the major... 
SUPPLEMENTATION | OXIDATION | BODY-FAT | OBESITY | LIPID-METABOLISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | FOOD SCIENCE & TECHNOLOGY | THEANINE | EPIGALLOCATECHIN GALLATE | CATECHINS | ANTIOXIDANT PROPERTIES | EXTRACT | Camellia sinensis - chemistry | Liver - pathology | Adipose Tissue, White - immunology | Obesity - immunology | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Dietary Supplements - analysis | Liver - immunology | Polysaccharides - administration & dosage | Hypolipidemic Agents - chemistry | Polysaccharides - therapeutic use | Hypolipidemic Agents - analysis | Anti-Obesity Agents - administration & dosage | Specific Pathogen-Free Organisms | Anti-Inflammatory Agents, Non-Steroidal - analysis | Plant Extracts - isolation & purification | Random Allocation | Hyperlipidemias - prevention & control | Rats, Sprague-Dawley | Obesity - pathology | Anti-Obesity Agents - chemistry | Obesity - prevention & control | Polyphenols - analysis | Hypolipidemic Agents - therapeutic use | Polyphenols - therapeutic use | Plant Extracts - therapeutic use | Leptin - antagonists & inhibitors | Plant Extracts - chemistry | Caffeine - analysis | Caffeine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Anti-Obesity Agents - analysis | Plant Extracts - administration & dosage | Leptin - blood | Caffeine - therapeutic use | Polysaccharides - isolation & purification | Food Handling | Cytokines - blood | Plant Leaves - chemistry | Adipose Tissue, White - pathology | Polyphenols - isolation & purification | Polysaccharides - analysis | Caffeine - isolation & purification | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hyperlipidemias - etiology | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Hypolipidemic Agents - administration & dosage | Cytokines - antagonists & inhibitors | Polyphenols - administration & dosage | Index Medicus
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 04/2013, Volume 65, Issue 4, pp. 494 - 502
Objectives Simvastatin has recently been demonstrated to serve as a therapeutic agent for osteoporosis. However, it is hard to dissolve in water and has side... 
simvastatin | deoxycholic acid | micelles | osteoporosis | calcium phosphate | OSTEOCLAST | APATITE FORMATION | SIMULATED BODY-FLUID | PHARMACOLOGY & PHARMACY | STATINS | BONE-RESORPTION | Simvastatin - therapeutic use | Surface-Active Agents - adverse effects | Simvastatin - adverse effects | Humans | Deoxycholic Acid - chemistry | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Nanocapsules - adverse effects | Nanocapsules - chemistry | Bone and Bones - drug effects | Deoxycholic Acid - adverse effects | Micelles | Surface Properties | Calcium Phosphates - adverse effects | Drug Compounding | Female | Deoxycholic Acid - administration & dosage | Hypolipidemic Agents - chemistry | Bone Density Conservation Agents - chemistry | Disease Models, Animal | Cell Line | Hypolipidemic Agents - adverse effects | Bone Density Conservation Agents - adverse effects | Simvastatin - chemistry | Simvastatin - administration & dosage | Bone Density Conservation Agents - therapeutic use | Calcium Phosphates - chemistry | Deoxycholic Acid - therapeutic use | Bone Density Conservation Agents - administration & dosage | Random Allocation | Mice, Inbred Strains | Osteoporosis, Postmenopausal - drug therapy | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Hypolipidemic Agents - administration & dosage | Hypolipidemic Agents - therapeutic use | Mice | Surface-Active Agents - chemistry | Drug Delivery Systems - adverse effects | Osteoporosis | Calcium phosphate | Health aspects | Analysis | Simvastatin | Deoxycholic acid | Calcium | Medical treatment | Index Medicus
Journal Article
Food and Function, ISSN 2042-6496, 3/2015, Volume 6, Issue 3, pp. 834 - 841
The present study investigated the anti-obesity and anti-diabetic effects of kaempferol glycoside (KG) fractions which were composed of four kaempferol... 
ENERGY-BALANCE | QUERCETIN | CELLS | OBESITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | FOOD SCIENCE & TECHNOLOGY | GLUCOSIDES | KINASE | ALPHA | ABSORPTION | Glycated Hemoglobin A - analysis | Humans | Male | Anti-Obesity Agents - therapeutic use | Dietary Supplements - analysis | Soybeans - growth & development | Glycosides - isolation & purification | Kaempferols - isolation & purification | Diabetes Mellitus, Type 2 - etiology | Obesity - etiology | Hypolipidemic Agents - chemistry | Kaempferols - analysis | Glycosides - chemistry | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - analysis | Kaempferols - chemistry | Obesity - complications | Diabetes Mellitus, Type 2 - prevention & control | Hypolipidemic Agents - isolation & purification | Lipid Metabolism | Plant Extracts - isolation & purification | Random Allocation | Hypoglycemic Agents - isolation & purification | Soybeans - chemistry | Anti-Obesity Agents - chemistry | Plant Leaves - growth & development | Obesity - prevention & control | Hypolipidemic Agents - therapeutic use | Plant Extracts - therapeutic use | Plant Extracts - chemistry | Hypoglycemic Agents - analysis | Diet, High-Fat - adverse effects | Anti-Obesity Agents - analysis | Kaempferols - therapeutic use | Diabetes Mellitus, Type 2 - metabolism | Adiposity | Diabetes Mellitus, Type 2 - complications | Plant Leaves - chemistry | Glycosides - analysis | Mice, Inbred C57BL | Insulin Resistance | Hypertriglyceridemia - metabolism | Hypoglycemic Agents - chemistry | Anti-Obesity Agents - isolation & purification | Obesity - metabolism | Hypertriglyceridemia - prevention & control | Animals | Hypertriglyceridemia - complications | Hypertriglyceridemia - etiology | Glycosides - therapeutic use | Index Medicus
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 04/2013, Volume 65, Issue 4, pp. 591 - 603
This study was carried out to assess the anti-obesity effect of Hypericum silenoides Juss. and Hypericum philonotis Cham. & Schlecht. in male Wistar rats fed... 
anti‐obesity natural products | tlanchalagua | cafeteria diet | ypericum philonotis | ypericum silenoides | Hypericum philonotis | anti-obesity natural products | Hypericum silenoides | Obesity - drug therapy | Rats, Wistar | Plant Extracts - pharmacology | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Antidepressive Agents - isolation & purification | Depression - etiology | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Plant Extracts - administration & dosage | Hypoglycemic Agents - administration & dosage | Lipase - antagonists & inhibitors | Hypericum - growth & development | Antidepressive Agents - pharmacology | Plant Components, Aerial - growth & development | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Anti-Obesity Agents - administration & dosage | Plant Components, Aerial - chemistry | Enzyme Inhibitors - pharmacology | Hypolipidemic Agents - isolation & purification | Rats | Obesity - physiopathology | Plant Extracts - isolation & purification | Random Allocation | Hypolipidemic Agents - pharmacology | Enzyme Inhibitors - therapeutic use | Hyperlipidemias - prevention & control | Anti-Obesity Agents - isolation & purification | Enzyme Inhibitors - isolation & purification | Hypoglycemic Agents - pharmacology | Antidepressive Agents - therapeutic use | Hypoglycemic Agents - isolation & purification | Ethnopharmacology | Animals | Depression - prevention & control | Hyperlipidemias - etiology | Hypolipidemic Agents - administration & dosage | Antidepressive Agents - administration & dosage | Mexico | Hyperglycemia - etiology | Hypolipidemic Agents - therapeutic use | Medicine, Traditional | Anti-Obesity Agents - pharmacology | Plant Extracts - therapeutic use | Hypericum - chemistry | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2013, Volume 15, Issue 11, pp. 1040 - 1048
AimsPostprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady-state liraglutide 1.8mg... 
lipid‐lowering therapy | study | randomized trial | 1 analogue | antidiabetic drug | GLP | phase I | type | diabetes | Type II diabetes | Randomized trial | Antidiabetic drug | Lipid-lowering therapy | GLP-1 analogue | Phase I-II study | LIPEMIA | OXIDATIVE STRESS | RECEPTOR AGONISTS | EXENATIDE | ACID BREATH TEST | INSULIN RESPONSES | MELLITUS | type II diabetes | lipid-lowering therapy | phase I-II study | THERAPY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | GLUCAGON | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diet, High-Fat - adverse effects | Half-Life | Glucagon-Like Peptide 1 - blood | Male | Hypoglycemic Agents - blood | Cardiovascular Diseases - complications | Hypolipidemic Agents - blood | Lipids - blood | Postprandial Period | Cardiovascular Diseases - epidemiology | Female | Glucagon-Like Peptide 1 - pharmacokinetics | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - adverse effects | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Risk Factors | Hyperlipidemias - prevention & control | Germany - epidemiology | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Hyperlipidemias - etiology | Denmark - epidemiology | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypolipidemic Agents - pharmacokinetics | Hypoglycemic Agents - adverse effects | Liraglutide | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Triglycerides | Glucose | Fatty acids | Cholesterol | Dextrose | Glucose metabolism | Hypoglycemic agents | Diabetes therapy | Lipids | Diet | Apolipoproteins | Index Medicus
Journal Article
Biomedicine & Pharmacotherapy, ISSN 0753-3322, 11/2017, Volume 95, pp. 1749 - 1758
Dyslipidemia, oxidative stress and inflammation are major risky factors involved in the pathophysiology of type 2 diabetes mellitus and atherosclerosis.... 
Antihyperlipidemia | Antioxidant | Hydroxytyrosol-fenofibrate | Anti-diabetes | Anti-inflammation | MEDICINE, RESEARCH & EXPERIMENTAL | TRIGLYCERIDE | OXIDATIVE STRESS | HIGH-FAT DIET | PHENOLIC-COMPOUNDS | ALPHA | HYPERTRIGLYCERIDEMIA | METABOLISM | OLIVE OIL | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | AGENTS | Diabetes Mellitus, Experimental - drug therapy | Phenylethyl Alcohol - administration & dosage | Antioxidants - chemistry | Phenylethyl Alcohol - analogs & derivatives | Male | Fenofibrate - chemistry | Fenofibrate - pharmacology | Hypoglycemic Agents - administration & dosage | Drug Design | Anti-Inflammatory Agents - administration & dosage | Hypolipidemic Agents - chemistry | Anti-Inflammatory Agents - pharmacology | Fenofibrate - administration & dosage | Hypoglycemic Agents - chemistry | Antioxidants - pharmacology | Hypolipidemic Agents - pharmacology | Chemistry, Pharmaceutical | Mice, Inbred ICR | Hypoglycemic Agents - pharmacology | Phenylethyl Alcohol - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | Hypolipidemic Agents - administration & dosage | Mice | Oxidative Stress - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Phenylethyl Alcohol - chemistry | Antioxidants | Anti-inflammatory drugs | Anticholesteremic agents | Type 2 diabetes | Analysis | Pharmacy | Atherosclerosis | Drugstores | Triglycerides | Index Medicus
Journal Article
Journal of Ethnopharmacology, ISSN 0378-8741, 04/2015, Volume 164, pp. 229 - 238
(Gaertn.) DC. (RG) has been widely used as traditional Chinese herbal medicine for treatment of diabetes and its complications. The polysaccharide fraction of... 
Oxidative stress | Rehmannia glutinosa | Inflammation | Diabetes | Polysaccharide | Insulin | Oxidativestress | CHEMISTRY, MEDICINAL | NITRIC-OXIDE SYNTHASE | INSULIN-SECRETION | FACTOR-ALPHA | PLANT SCIENCES | TUMOR-NECROSIS-FACTOR | PANCREATIC-ISLETS | INTEGRATIVE & COMPLEMENTARY MEDICINE | CULTURED U937 MONOCYTES | MEMBRANE LIPID-PEROXIDATION | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | MOLECULAR-MECHANISMS | Diabetes Mellitus, Experimental - drug therapy | Antioxidants - chemistry | Streptozocin | Cholesterol - blood | Diabetes Mellitus, Type 1 - metabolism | Superoxide Dismutase - blood | Male | Diabetes Mellitus, Experimental - blood | Glycogen - metabolism | Liver - drug effects | Anti-Inflammatory Agents - therapeutic use | Polysaccharides - chemistry | Molecular Structure | Hypolipidemic Agents - chemistry | Diabetes Mellitus, Experimental - metabolism | Cytokines - blood | Hypoglycemic Agents - therapeutic use | Polysaccharides - therapeutic use | Anti-Inflammatory Agents - pharmacology | Glutathione Peroxidase - blood | Liver - metabolism | Pancreas - drug effects | Hypoglycemic Agents - chemistry | Antioxidants - pharmacology | Pancreas - metabolism | Hypolipidemic Agents - pharmacology | Polysaccharides - pharmacology | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - pharmacology | Antioxidants - therapeutic use | Insulin - metabolism | Animals | Anti-Inflammatory Agents - chemistry | Rehmannia | Diabetes Mellitus, Type 1 - blood | Triglycerides - blood | Hypolipidemic Agents - therapeutic use | Mice | Polysaccharides | Hyperglycemia | Index Medicus
Journal Article
Stroke, ISSN 0039-2499, 05/2018, Volume 49, Issue 5, pp. 1148 - 1154
Journal Article
Medicina Clinica, ISSN 0025-7753, 02/2016, Volume 146, Issue 4, pp. 172 - 177
An elevated proportion of high cardiovascular risk patients do not achieve the therapeutic c-LDL goals. This owes to physicians' inappropriate or insufficient... 
Hypolipidemic drugs | Hypercholesterolemia treatment | Arteriosclerosis | Lipid metabolism
Journal Article
Journal Article
Journal of the Science of Food and Agriculture, ISSN 0022-5142, 10/2014, Volume 94, Issue 13, pp. 2726 - 2737
BACKGROUNDSyzygium aromaticum (L.) Merr. & Perry (clove) bud is an important spice used in the preparation of several delicacies and in folklore for diabetes... 
high‐fat diet | clove bud powder | type 2 diabetes | streptozotocin | Type 2 diabetes | Streptozotocin | High-fat diet | Clove bud powder | OXIDATIVE STRESS | ACID | LIPID-PEROXIDATION | FOOD SCIENCE & TECHNOLOGY | CINNAMON | L. MERR | IN-VITRO | HYPERGLYCEMIA | GLUTATHIONE | high-fat diet | AGRICULTURE, MULTIDISCIPLINARY | CHEMISTRY, APPLIED | CONVERTING-ENZYME | EXTRACT | Liver - enzymology | Oxidative Stress | Rats, Wistar | Diet, High-Fat - adverse effects | Diabetes Mellitus, Type 2 - diet therapy | Male | Plant Preparations - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Flowers - chemistry | Liver - physiopathology | Syzygium - growth & development | Non-alcoholic Fatty Liver Disease - complications | Syzygium - chemistry | Phytotherapy - adverse effects | Hypoglycemic Agents - administration & dosage | Plant Preparations - therapeutic use | Medicine, African Traditional | Dietary Supplements - adverse effects | Plant Preparations - adverse effects | Nigeria | Diabetes Mellitus, Type 2 - complications | Biomarkers - metabolism | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - adverse effects | Liver - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Non-alcoholic Fatty Liver Disease - physiopathology | Random Allocation | Flowers - growth & development | Lipotropic Agents - therapeutic use | Antioxidants - therapeutic use | Ethnopharmacology | Lipotropic Agents - administration & dosage | Animals | Diabetes Mellitus, Type 2 - physiopathology | Lipotropic Agents - adverse effects | Antioxidants - administration & dosage | Hypolipidemic Agents - administration & dosage | Antioxidants - adverse effects | Hypolipidemic Agents - therapeutic use | Non-alcoholic Fatty Liver Disease - diet therapy | Hypoglycemic Agents - adverse effects | Antioxidants | Enzymes | Powders | Streptozocin | Blood sugar | Aspartate | Superoxide | Diet | Rodents | Biochemistry | Diabetes | Disease management | Flowers & plants | Index Medicus | Diets | Hyperglycemia | Alanine | Catalase | Symbols | Rats
Journal Article
Medical Care, ISSN 0025-7079, 4/2009, Volume 47, Issue 4, pp. 395 - 402
Background: Intensification of pharmacotherapy in persons with poorly controlled chronic conditions has been proposed as a clinically meaningful process... 
Hypertension | Hyperlipidemias | Trajectory control | Diabetes mellitus | Ales | Predisposing factors | Medications | Internships | Diabetes | Hemoglobins | Cardiovascular disease | Hyperlipidemia | Quality of health care | UNITED-STATES | cardiovascular disease | hyperlipidemia | quality of health care | MANAGEMENT | CHOLESTEROL | HYPERTENSION CONTROL | TRANSLATING RESEARCH | diabetes mellitus | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HEALTH CARE SCIENCES & SERVICES | BLOOD-PRESSURE CONTROL | HEALTH POLICY & SERVICES | CORONARY-HEART-DISEASE | hypertension | TYPE-2 DIABETES-MELLITUS | OF-CARE | PERFORMANCE-MEASURES | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Hyperlipidemias - drug therapy | Middle Aged | Risk Factors | Diabetes Mellitus - drug therapy | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | California | Antihypertensive Agents - therapeutic use | Managed Care Programs | Outcome and Process Assessment (Health Care) | Drug Therapy - standards | Hypoglycemic Agents - administration & dosage | Drug Therapy - methods | Hypolipidemic Agents - administration & dosage | Female | Aged | Hypolipidemic Agents - therapeutic use | Quality Indicators, Health Care - standards | Chronic Disease - drug therapy | Performance evaluation | Validity | Drug therapy | Risk factors | Quality of care | Chronic illnesses | Index Medicus
Journal Article